Pharma IQ Members

Bertil
Lindmark

Bertil Lindmark
In this, the latest in our Boardroom Series of interviews, Bertil Lindmark praises the manoeuvrability of smaller pharma companies. He argues that the current in vivo models need revising and that single-point interventions may not be the best strategy for pharmaceuticals...Full Article »